[Percutaneous intrahepatic portosystemic shunting as a treatment for refractory hepatic hydrothorax].
|
| Abstract |
Hepatic hydrothorax is an infrequent complication of portal hypertension in liver cirrhosis. Treatment with saline restriction and diuretics is usually effective but when this fails, the therapeutic approach is difficult and multiple complications occur. Transjugular percutaneous intrahepatic portosystemic shunt (IPS) is associated with a marked decrease in portal pressure and consequently this technique has been used in the treatment of refractory ascites. The aim of this study was to analyze the efficacy, safety and outcome of refractory hepatic hydrothorax treated by IPS. The procedure was performed in 5 patients who were all grade B or C in the Child-Pugh classification. Three patients showed complete response to the treatment, of whom 1 underwent transplantation 20 days later. The fourth patient showed partial response with a reduction in the need to perform thoracocentesis and the fifth patient showed no response to IPS and died after 17 days of follow-up. Albumin levels and Child classification remained unchanged. Two patients presented recurrence with reappearance of hydrothorax due to shunt dysfunction and 2 patients presented hepatic encephalopathy that responded to medical treatment. Refractory hepatic hydrothorax can be controlled by IPS in a large number of patients but its efficacy is restricted by shunt dysfunction, the risk of encephalopathy and by its limited effect on survival.
|
|---|---|
| Authors | O Núñez, A García, D Rincón, S Alonso, A Echenagusía, R Bañares |
| Journal | Gastroenterologia y hepatologia (Gastroenterol Hepatol) Vol. 25 Issue 3 Pg. 143-7 (Mar 2002) ISSN: 0210-5705 [Print] Spain |
| Vernacular Title | Derivación portosistémica percutánea intrahepática como tratamiento del hidrotórax hepático refractario. |
| PMID | 11864535 (Publication Type: Clinical Trial, English Abstract, Journal Article) |
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!